You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

CLINICAL TRIALS PROFILE FOR AVINZA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for AVINZA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00488969 ↗ Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury Completed U.S. Department of Education Phase 2 2007-07-01 We would like to learn if a medicine called "modified-release morphine sulfate" (Avinza) helps reduce Spinal Cord Injury (SCI)-related pain that has lasted a long time. "Modified-release" means that the medicine in the capsules is slowly released to the body, instead of being released all at once. Avinza is approved by the Food and Drug Administration for the treatment of pain, but we do not know how effective Avinza is in reducing SCI-related pain.
NCT00488969 ↗ Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury Completed Icahn School of Medicine at Mount Sinai Phase 2 2007-07-01 We would like to learn if a medicine called "modified-release morphine sulfate" (Avinza) helps reduce Spinal Cord Injury (SCI)-related pain that has lasted a long time. "Modified-release" means that the medicine in the capsules is slowly released to the body, instead of being released all at once. Avinza is approved by the Food and Drug Administration for the treatment of pain, but we do not know how effective Avinza is in reducing SCI-related pain.
NCT00640042 ↗ Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza Completed Pfizer Phase 4 2008-03-01 The purpose of this study is to provide information in a broad, "real world" population of chronic pain patients assessing both pain control with AVINZA as well as the potential risk for misuse and abuse.
NCT00782548 ↗ Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults Completed Actavis Inc. Phase 4 2004-05-01 The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30 mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed conditions. The secondary objective of this study was to evaluate the adverse events associated with each of these 2 different morphine sulfate modified-release commercial formulations
NCT00782548 ↗ Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults Completed Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc. Phase 4 2004-05-01 The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30 mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed conditions. The secondary objective of this study was to evaluate the adverse events associated with each of these 2 different morphine sulfate modified-release commercial formulations
NCT00994383 ↗ Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled Release Completed Roxane Laboratories N/A 2007-01-01 Characterize the steady-state pharmacokinetics of morphine after oral administration of Roxane Laboratories' morphine sulfate immediate release tablets and oral solution and to compare their pharmacokinetics to that of AVINZA.
NCT01538745 ↗ Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department Completed U.S. Air Force Office of the Surgeon General Phase 4 2012-02-01 The purpose of this study is to compare the safety and effectiveness of intravenous low dose ketamine (LDK) to the industry standard of morphine (MOR) in regards to controlling acute pain in the emergency department. Both LDK and morphine have side effects. The amount and character of these side effects will be compared. Additionally, the degree of sedation or agitation will be specifically measured. The aim of this current study is to make this comparison and shift the evidence for LDK use from the anecdotal to the scientific.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AVINZA

Condition Name

Condition Name for AVINZA
Intervention Trials
Pain 3
Back Pain 1
Metastatic Malignant Solid Neoplasm 1
Back Pain, Acute 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for AVINZA
Intervention Trials
Flank Pain 1
Spinal Cord Injuries 1
Emergencies 1
Neoplasms, Second Primary 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AVINZA

Trials by Country

Trials by Country for AVINZA
Location Trials
United States 40
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for AVINZA
Location Trials
Texas 4
New York 2
South Carolina 1
Pennsylvania 1
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AVINZA

Clinical Trial Phase

Clinical Trial Phase for AVINZA
Clinical Trial Phase Trials
Phase 4 3
Phase 2/Phase 3 1
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for AVINZA
Clinical Trial Phase Trials
Completed 6
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AVINZA

Sponsor Name

Sponsor Name for AVINZA
Sponsor Trials
Isfahan University of Medical Sciences 1
National Cancer Institute (NCI) 1
M.D. Anderson Cancer Center 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for AVINZA
Sponsor Trials
Industry 4
U.S. Fed 3
Other 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.